Literature DB >> 11107439

Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.

D R Budman1, A Calabro, L G Wang, X M Liu, L Stiel, L M Adams, W Kreis.   

Abstract

Empiric combinations of vinca alkaloids with taxanes have been recently used in clinical oncology. To enhance the activity of these two classes of agents, we evaluated the sequence and duration of exposure, looking for synergistic effects. Cell lines DU 145, PC 3, LnCaP, LL 86, MCF7wt, and MCF7/ADR (NCI/ADR-RES) were incubated with varying concentrations of paclitaxel or vinorelbine. Cytotoxicity was evaluated by a semiautomated MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) method. Synergism or antagonism of these two agents either sequentially or in combination was determined by median effect analysis. Prolonged exposure of cells to either drug enhanced cytotoxic effect. Synergism or antagonism with vinorelbine and paclitaxel were both sequence dependent and cell line specific. In the case of MCF7wt, synergism was seen when a 48-hr exposure to vinorelbine preceded paclitaxel, whereas antagonism was noted when both agents were applied simultaneously or when the sequence was reversed. Concurrent vinorelbine and paclitaxel were synergistic in four of six cell lines when the exposure was extended to 96 hr but not for shorter durations of exposure. Sequential exposure of vinorelbine preceding paclitaxel or prolonged exposure to both agents concurrently needs to be tested clinically to determine whether the antitumor activity of this combination can be enhanced. In addition, these studies suggest concurrent administration of these two agents may lead to a less than optimal cytotoxic result.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107439     DOI: 10.3109/07357900009012201

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  6 in total

1.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

2.  SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.

Authors:  Robert B Livingston; William E Barlow; Joseph J Kash; Kathy S Albain; Julie R Gralow; Danika L Lew; Lawrence E Flaherty; Melanie E Royce; Gabriel N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  2011-08-09       Impact factor: 4.872

3.  Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.

Authors:  X M Liu; L G Wang; W Kreis; D R Budman; L M Adams
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

4.  Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.

Authors:  A Berruti; R Bitossi; G Gorzegno; A Bottini; D Generali; M Milani; D Katsaros; I A Rigault de la Longrais; R Bellino; M Donadio; M Ardine; O Bertetto; S Danese; M G Sarobba; A Farris; V Lorusso; L Dogliotti
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

5.  The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.

Authors:  Graham Skelhorne-Gross; Christopher J B Nicol
Journal:  PPAR Res       Date:  2012-07-02       Impact factor: 4.964

6.  Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells.

Authors:  X M Liu; J D Jiang; A C Ferrari; D R Budman; L G Wang
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.